Skip to main content


Freshfields advises the independent board of Haleon on the planned demerger from GSK

Freshfields Bruckhaus Deringer (‘Freshfields’) is acting as independent counsel to Haleon plc on its planned demerger from GSK plc and its listing on the London Stock Exchange, expected in July 2022. GSK shareholders must first approve the demerger at a meeting which is convened for 6 July 2022. Haleon is currently a joint venture between GSK and Pfizer Inc.

Expected to be the largest listing in London for many years and amongst the largest ever demergers in Europe, Haleon will be one of the world's leading consumer healthcare companies.

The Freshfields team working with the Haleon team (led by General Counsel Bjarne Tellmann, Company Secretary Amanda Mellor and Head of Corporate Legal Charles Atkinson) in advising the new Board of Haleon is led by global transactions partners Julian Long and Samira Afrasiabi with tax partner May Smith, people and reward partners Alice Greenwell and David Mendel, finance partners Martin Hutchings and Duncan Kellaway, and IP counsel Jon Scurr.